@article{oai:kanazawa-u.repo.nii.ac.jp:00058988,
 author = {小川, 数馬 and 三代, 憲司 and 柴, 和弘 and 絹谷, 清剛 and 小谷, 明 and Ogawa, Kazuma and Takeda, Takuya and Mishiro, Kenji and Toyoshima, Atsushi and Shiba, Kazuhiro and Yoshimura, Takashi and Shinohara, Atsushi and Kinuya, Seigo and Odani, Akira},
 issue = {3},
 journal = {ACS Omega},
 month = {},
 note = {Alpha particle-emitting radionuclides have gained considerable attention for radionuclide therapy. Astatine-211 ( 211 At) is a promising alpha particle-emitting radionuclide. 211 At is a halogen that has similar chemical properties to iodine and exhibits a half-life of 7.2 h. However, direct labeling of proteins or peptides into the tyrosine residue with 211 At was shown to be impractical. Herein, we demonstrate a novel 211 At-labeling method using the RGD peptide as a model peptide. An 211 At-labeled RGD peptide, [ 211 At]c[RGDf(4-At)K], was prepared from a precursor with a tributylstannyl group on the phenylalanine residue in c(RGDfK) with a radiochemical yield of 63% and a radiochemical purity of >96%, and its potential for targeted radionuclide therapy was evaluated. Based on the results of biodistribution experiments, [ 125 I]c[RGDf(4-I)K] and [ 211 At]c[RGDf(4-At)K] showed high accumulation in the tumor and similar biodistribution. This study provides useful information for radiotheranostics between an 211 At-labeled peptide and the corresponding radioiodine-labeled peptide. © 2019 American Chemical Society., This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes., 金沢大学疾患モデル総合研究センター},
 pages = {4584--4591},
 title = {Radiotheranostics coupled between an At-211-Labeled RGD peptide and the corresponding radioiodine-labeled RGD peptide},
 volume = {4},
 year = {2019}
}